![]()
|
|
||||||||
J. Biol. Chem., Vol. 280, Issue 48, 40097-40103, December 2, 2005
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1
1




2
From the
Departments of Biochemistry and
Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee, 37232 ¶Department of Biochemistry, St. Jude Children's Research Hospital, and Department of Molecular Sciences, University of Tennessee, Memphis, Tennessee, 38105 ||Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, 35294 **Department of Pathology, Vanderbilt University Medical Center, Nashville, Tennessee, and 
Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232
The inv(16) is one of the most frequent chromosomal translocations associated with acute myeloid leukemia (AML) and creates a chimeric fusion protein consisting of most of the runt-related X1 co-factor, core binding factor
fused to the smooth muscle myosin heavy chain MYH11. Expression of the ARF tumor suppressor is regulated by runt-related X1, suggesting that the inv(16) fusion protein (IFP) may repress ARF expression. We established a murine bone marrow transplant model of the inv(16) in which wild type, Arf+/-, and Arf-/- bone marrow were engineered to express the IFP. IFP expression was sufficient to induce a myelomonocytic AML even when expressed in wild type bone marrow, yet removal of only a single allele of Arf greatly accelerated the disease, indicating that Arf is haploinsufficient for the induction of AML in the presence of the inv(16).
Received for publication, June 23, 2005 , and in revised form, September 26, 2005.
* This work was supported by Vanderbilt-Ingram Cancer Center Grant CA68485 and National Institutes of Health Grants RO1-CA87549, RO1-CA64140, RO1-CA77274 (to S. W. H.) and RO1-CA76379 (to J. L. C.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 These authors contributed equally to this work.
2 To whom correspondence should be addressed: Dept. of Biochemistry, Vanderbilt University School of Medicine, PRB 512, 23rd and Pierce, Nashville, Tennessee 37232. Tel.: 615-936-3582; Fax: 615-936-1790; E-mail: scott.hiebert{at}vanderbilt.edu.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
H.-G. Kim, K. Kojima, C. S. Swindle, C. V. Cotta, Y. Huo, V. Reddy, and C. A. Klug FLT3-ITD cooperates with inv(16) to promote progression to acute myeloid leukemia Blood, February 1, 2008; 111(3): 1567 - 1574. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Markus, M. T. Garin, J. Bies, N. Galili, A. Raza, M. J. Thirman, M. M. Le Beau, J. D. Rowley, P. P. Liu, and L. Wolff Methylation-Independent Silencing of the Tumor Suppressor INK4b (p15) by CBF{beta}-SMMHC in Acute Myelogenous Leukemia with inv(16) Cancer Res., February 1, 2007; 67(3): 992 - 1000. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Wunderlich, O. Krejci, J. Wei, and J. C. Mulloy Human CD34+ cells expressing the inv(16) fusion protein exhibit a myelomonocytic phenotype with greatly enhanced proliferative ability Blood, September 1, 2006; 108(5): 1690 - 1697. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |